Bang H. Hoang, M.D.

Bang Hoang, M.D. is a board-certified orthopeadic surgeon at Montefiore Einstein Health System who specializes in treating patients with bone and soft tissue tumors. Dr. Hoang is a graduate of UCLA David Geffen School of Medicine and completed his residency in orthopaedic surgery at Case Western Reserve University Hospitals. During medical school, he was awarded a Howard Hughes fellowship to receive training at the National Institutes of Health in Bethesda, MD. After residency, he completed a fellowship in orthopaedic oncology at Memorial Sloan-Kettering Cancer Center in New York. Before coming to Montefiore-Einstein, he was Director of the Multidisciplinary Sarcoma Center at the Univ of California, Irvine Healthcare system in Orange County, CA (sarcomas are tumors arising from nerves, blood vessels, fat, muscles, bones, and other connective tissues). He is currently Professor in the Department of Orthopaedic Surgery and holds the Arnold S. and Madaleine Penner Endowed Chair in Orthopaedic Oncology. He is also Co-Director of the Orthopaedic Oncology Division at Montefiore Einstein. His clinical practice is focused on musculoskeletal oncology, and in particular, the treatment of adults and children with benign and malignant bone and soft tissue tumors and metastatic bone disease. He has served on several grant funding and educational committees for the American Academy of Orthopaedic Surgeons and the Orthopaedic Research and Education Foundation. Currently, he serves on the executive board as a committee chair for the Musculoskeletal Tumor Society, the largest association of bone tumor surgeons in the U.S.

Besides his clinical practice, Dr. Hoang also heads a research team at Montefiore Einstein that developed genetically engineered and human-derived xenograft models of sarcoma. These models have been used widely by researchers to understand the complex tumor microenvironments of bone and soft tissue sarcomas and to find new therapies which target signaling pathways and mutations in major tumor suppressor genes, such as Rb1 and p53. Currently, he is leading a team at Montefiore Einstein that receives R01 funding from the National Cancer Institute to develop genetically engineered models and bioinformatic pipelines to study the impact of the proteosome degradation pathway in pediatric sarcoma and to develop new treatments for these cancers.

In 2007, the American Orthopaedic Association selected Dr. Hoang for its flagship North American Traveling Fellowship. During the month-long fellowship, he was invited to lecture at several academic institutions in the U.S. and Canada, including Harvard-MGH, Johns Hopkins, Univ of Maryland-Shock Trauma, Rothman, Darmouth, McGill, and Emory, among others. For their work on the pathogenesis of osteosarcoma, Hoang and his colleagues Yi Guo (Albert Einstein), Randall Holcombe (Univ of Vermont), and Xiaolin Zi (UC Irvine), were awarded the 2011 Kappa Delta Ann Doner Vaughn Award. Since 1950, the Kappa Delta Award has been given by the American Academy of Orthopedic Surgeons to recognize clinical research with the highest impact on musculoskeletal diseases. In addition, Hoang's work on the VEGF-Neuropilin axis as a novel therapeutic target for osteosarcoma was also recognized by the 2011 Career Development Award from the Orthopaedic Research and Education Foundation.